Literature DB >> 18403951

First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report.

Ioannis G Baraboutis1, Vassilios Papastamopoulos, Georgios Charitsis, Lazaros J Lekakis, Michael M Vaslamatzis, Athanasios T Skoutelis.   

Abstract

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403951     DOI: 10.1097/MEG.0b013e3282f16411

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  1 in total

1.  Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Authors:  Nicolas Magné; Cyrus Chargari; Antonin Levy; Jean-Baptiste Guy; Yacine Merrouche; Jean-Philippe Spano
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.